Coherus Oncology, Inc. (CHRS) Financial Ratios
14 years of historical data (2012–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
30Y Low8.2·High12.0
P/FCF
N/A
—
5yr avg: N/A
30Y Low9.9·High85.2
P/B Ratio
↓
3.47
↓-54% vs avg
5yr avg: 7.56
30Y Low2.0·High64.9
ROE
↑
275.4%
↓+345% vs avg
5yr avg: 61.9%
30Y Low-359%·High275%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low1.7·High2.6
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CHRS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Coherus Oncology, Inc. trades at 1.2x earnings, 62% below its 5-year average of 3.3x, sitting at the 25th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.3x, the stock trades at a discount of 94%.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $213M | $171M | $158M | $314M | $615M | $1.2B | $1.5B | $1.3B | $589M | $468M | $1.2B |
| Enterprise Value | $126M | $84M | $302M | $692M | $1.0B | $1.2B | $1.3B | $1.3B | $619M | $442M | $1.2B |
| P/E Ratio → | 1.23 | 0.99 | 5.52 | — | — | — | 10.73 | 14.64 | — | — | — |
| P/S Ratio | 5.06 | 4.05 | 0.59 | 1.22 | 2.91 | 3.69 | 3.05 | 3.70 | 378.26 | 300.50 | 6.21 |
| P/B Ratio | 3.47 | 2.80 | — | — | — | 12.32 | 5.16 | 12.52 | — | 15.99 | 64.89 |
| P/FCF | — | — | — | — | — | — | 9.88 | 85.24 | — | — | — |
| P/OCF | — | — | — | — | — | — | 9.41 | 46.47 | — | — | — |
P/E links to full P/E history page with 30-year chart
CHRS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.98 | 1.13 | 2.69 | 4.89 | 3.69 | 2.79 | 3.73 | 398.01 | 284.11 | 6.08 |
| EV / EBITDA | — | — | — | — | — | — | 8.23 | 11.97 | — | — | — |
| EV / EBIT | — | — | 5.43 | — | — | — | 8.46 | 12.33 | — | — | — |
| EV / FCF | — | — | — | — | — | — | 9.03 | 85.95 | — | — | — |
CHRS Profitability
Margins and return-on-capital ratios measuring operating efficiency
Coherus Oncology, Inc. earns an operating margin of -429.5%. Operating margins have compressed from -79.0% to -429.5% over the past 3 years, signaling potential cost pressures or competitive headwinds. Return on equity of 275.4% is exceptionally high, though this is partly amplified by negative book value driven by aggressive share buybacks.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -37.3% | -37.3% | 56.0% | 38.2% | 66.8% | 82.4% | 92.1% | 95.2% | -107.9% | -10216.9% | -33.8% |
| Operating Margin | -429.5% | -429.5% | -41.8% | -79.0% | -121.7% | -80.8% | 32.9% | 30.3% | -13137.3% | -14918.8% | -61.0% |
| Net Profit Margin | 398.4% | 398.4% | 10.7% | -92.5% | -138.2% | -87.9% | 27.8% | 25.2% | -13453.7% | -15306.6% | -67.0% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 275.4% | 275.4% | — | — | — | -151.6% | 68.5% | 269.7% | — | -1004.4% | -2418.6% |
| ROA | 47.5% | 47.5% | 5.3% | -42.8% | -50.3% | -37.8% | 21.1% | 35.3% | -159.8% | -139.6% | -65.2% |
| ROIC | — | — | -85.3% | -65.7% | -101.7% | -154.3% | 85.9% | 149.2% | — | — | — |
| ROCE | -127.8% | -127.8% | -48.2% | -63.5% | -60.0% | -43.6% | 31.6% | 59.8% | -204.0% | -181.1% | -101.5% |
CHRS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $89M exceeds total debt of $1M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | — | — | — | 4.29 | 1.48 | 1.79 | — | 3.47 | 5.51 |
| Debt / EBITDA | — | — | — | — | — | — | 2.59 | 1.70 | — | — | — |
| Net Debt / Equity | — | -1.43 | — | — | — | 0.02 | -0.44 | 0.10 | — | -0.87 | -1.36 |
| Net Debt / EBITDA | — | — | — | — | — | — | -0.77 | 0.10 | — | — | — |
| Debt / FCF | — | — | — | — | — | — | -0.84 | 0.71 | — | — | — |
| Interest Coverage | — | — | -4.11 | -5.01 | -7.91 | -11.49 | 7.39 | 6.12 | -21.11 | -24.30 | -14.53 |
Net cash position: cash ($89M) exceeds total debt ($1M)
CHRS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.38x means Coherus Oncology, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 1.43x to 1.38x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.38 | 1.38 | 1.21 | 1.43 | 2.75 | 3.64 | 5.27 | 2.98 | 2.18 | 4.47 | 2.22 |
| Quick Ratio | 1.35 | 1.35 | 0.96 | 1.24 | 2.47 | 3.42 | 4.97 | 2.90 | 2.13 | 4.47 | 2.30 |
| Cash Ratio | 1.23 | 1.23 | 0.45 | 0.35 | 1.38 | 2.52 | 3.72 | 1.55 | 2.18 | 4.47 | 2.22 |
| Asset Turnover | — | 0.16 | 0.60 | 0.41 | 0.44 | 0.48 | 0.57 | 0.87 | 0.02 | 0.01 | 1.07 |
| Inventory Turnover | 3.06 | 3.06 | 1.68 | 2.54 | 1.81 | 1.53 | 0.85 | 1.74 | 1.95 | — | — |
| Days Sales Outstanding | — | 154.19 | 167.26 | 369.65 | 190.18 | 137.51 | 120.47 | 145.55 | — | — | 3.57 |
CHRS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Coherus Oncology, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 81.3% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 81.3% | 100.7% | 18.1% | — | — | — | 9.3% | 6.8% | — | — | — |
| FCF Yield | — | — | — | — | — | — | 10.1% | 1.2% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% |
| Shares Outstanding | — | $120M | $115M | $94M | $78M | $75M | $83M | $73M | $65M | $53M | $42M |
Peer Comparison
Compare CHRS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CHRSYou | $213M | 1.2 | — | — | -37.3% | -429.5% | 275.4% | — | — |
 PRGO | $2B | -1.1 | 7.4 | 11.1 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 AMRX | $4B | 62.4 | — | 16.0 | 36.9% | -0.2% | 15.7% | -0.2% | — |
 HCM | $2B | 60.5 | — | — | 44.6% | -6.9% | 5.0% | -5.2% | — |
 TGTX | $7B | 15.5 | 57.1 | — | 83.6% | 20.0% | 102.8% | 16.4% | 2.1 |
 MGNX | $186M | -2.5 | — | — | — | -48.7% | -86.9% | -1879.3% | — |
 VTRS | $20B | -5.8 | 248.5 | 10.5 | 35.1% | -18.6% | -21.1% | -6.6% | 108.7 |
 PFGC | $15B | 42.5 | 14.7 | 20.7 | 11.7% | 1.3% | 7.9% | 5.7% | 5.2 |
 SGMT | $247M | -4.8 | — | — | — | — | -38.2% | -54.5% | — |
 AGEN | $132M | -1102.9 | — | — | 90.3% | -18.0% | — | — | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
See CHRS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CHRS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CHRS vs PRGO
Side-by-side business, growth, and profitability comparison vs Perrigo Company plc.
Start ComparisonCHRS — Frequently Asked Questions
Quick answers to the most common questions about buying CHRS stock.
What is Coherus Oncology, Inc.'s P/E ratio?
Coherus Oncology, Inc.'s current P/E ratio is 1.2x. The historical average is 8.0x. This places it at the 25th percentile of its historical range.
What is Coherus Oncology, Inc.'s ROE?
Coherus Oncology, Inc.'s return on equity (ROE) is 275.4%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 20.5%.
Is CHRS stock overvalued?
Based on historical data, Coherus Oncology, Inc. is trading at a P/E of 1.2x. This is at the 25th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Coherus Oncology, Inc.'s profit margins?
Coherus Oncology, Inc. has -37.3% gross margin and -429.5% operating margin.